MLN0905 is a potent, selective small-molecule PLK1 inhibitor. MLN0905 inhibits cell proliferation in a broad range of human tumor cells including DLBCL cell lines. PLK1 inhibition leads to pharmacodynamic pHisH3 modulation and significant antitumor activity in multiple DLBCL models. These data strongly suggest evaluating PLK1 inhibitors as DLBCL anticancer agents in the clinic. (source: Mol Cancer Ther; 11(9); 2045-53.)
臺(tái)州市科瑞生物技術(shù)有限公司
聯(lián)系商家時(shí)請(qǐng)?zhí)峒癱hemicalbook,有助于交易順利完成!
crene